Robert Lavender

Sourced from institutional research profiles (UAMS TRI or ARA).

Professor

UAMS

Faculty Researcher

Internal Med, College of Medicine

Research Areas

Links

Research Group UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

Robert Lavender is a Professor in the Department of Internal Medicine at the University of Arkansas for Medical Sciences. His research focuses on studying various aspects of health and disease within internal medicine. He has published work contributing to the broader field of health sciences research and education.

Grants & Funding

As listed on this researcher's institutional profile.

A randomized, 24-week, open-label, 2-arm parallel-group, multicenter study comparing the efficacy and safety of insulin gargine/lixisenatide fixed rat Sanofi Pasteur, Inc. Principal Investigator
A Phase III Randomized, double blind, parallel-group stuyd of the efficacy and safety of oral dabigatran etexilate (150 mg bid)compared to warffarin ( Boehringer Ingleheim Pharmaceuticals, Inc. Principal Investigator
Protocol #11702 entitled: “Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis and/or pulmonary emboli Bayer Corporation (Bayer USA) Principal Investigator
A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate cardiovascular outcomes during treatment with lixisenati Sanofi-Aventis Principal Investigator
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LM Daiichi Pharmaceutical Corporation Principal Investigator
A double-blind, placebo-controlled, parallel, multicenter study on extended VTE prophylaxix in acutely ill medical patients with prolonged immobilizat Aventis Pharmaceuticals, Inc. Principal Investigator
A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN IN THE TREATMENT OF SYMPTOMATIC DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM” Pfizer, Inc. Principal Investigator